BioCryst Strategy and Business Model

Executive Overview

BioCryst is a commercial-stage rare-disease biotechnology company headquartered in Durham, North Carolina, founded in 1986. The company focuses on discovering, developing, and commercializing small-molecule medicines for serious diseases where an oral therapy can offer a meaningful practical advantage. Its core commercial asset is ORLADEYO (berotralstat), a once-daily oral therapy for prevention of hereditary angioedema attacks. BioCryst also has RAPIVAB (peramivir), an intravenous antiviral for influenza, but ORLADEYO is the company’s clear economic engine and strategic center of gravity. In FY2024, BioCryst reported revenue of #N/A, driven primarily by ORLADEYO.

Strategically, BioCryst sits between two models: it is more focused than a diversified pharmaceutical company, yet more commercially established than a pre-revenue biotech. Its business now depends on using the ORLADEYO franchise to deepen penetration in hereditary angioedema, expand internationally, and fund a focused pipeline of additional oral rare-disease medicines, including complement-pathway programs. BioCryst operates mainly in the United States, Europe, and Japan, with additional reach through partners. The company’s appeal to investors and strategic partners rests on a simple proposition: combine rare-disease pricing and focused commercialization with oral-drug convenience and disciplined portfolio selection.

BioCryst at a Glance

Logo
Common name	BioCryst
Full legal name	BioCryst Pharmaceuticals, Inc.
Headquarters	Durham, North Carolina, United States
Ownership	Public company; listed on Nasdaq. Ownership is broadly institutional and public, with no controlling shareholder publicly disclosed.
Ticker	BCRX
Exchange	NASDAQ
Market Cap	$2.38B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1986; developed a long-standing small-molecule and antiviral research base; RAPIVAB approved in the U.S. in 2014; ORLADEYO approved in 2020, shifting BioCryst into a commercial rare-disease company.
Industry or industries	Biotechnology; rare-disease pharmaceuticals
Key products or services	ORLADEYO for hereditary angioedema prophylaxis; RAPIVAB for influenza; pipeline rare-disease programs including complement-pathway candidates
Geographic footprint	United States, Europe, Japan, and additional international markets through partners
Business segments as officially reported	One reportable segment
Company website	https://www.biocryst.com/

1. What Is the Strategy of BioCryst?

BioCryst’s public disclosures point to a focused rare-disease strategy: build a durable commercial franchise around ORLADEYO, use that franchise to support a concentrated pipeline, and compete where oral small molecules can deliver a meaningful advantage over injectable or infused therapies. Using the Playing to Win framework, the strategy looks like this:

1. 1a. What is the winning aspiration of BioCryst?

   BioCryst’s practical aspiration is to become a self-sustaining rare-disease company built around differentiated oral medicines. In management commentary and investor materials through FY2024, “winning” is not simply getting a drug approved; it is turning ORLADEYO into a durable global franchise and using that commercial base to create additional value from the pipeline. An informed reading of the company’s filings suggests that BioCryst wants to reduce dependence on repeated external financing by growing recurring product revenue and selectively reinvesting in high-conviction programs.

2. 1b. Where does BioCryst play?

   BioCryst plays in rare diseases with well-defined biology, high unmet need, and economics that can support focused commercialization. Its current core market is hereditary angioedema (HAE), especially long-term prophylaxis. Beyond HAE, the company has targeted complement-mediated diseases where oral inhibitors could be attractive. Geographically, BioCryst focuses on the United States and other developed pharmaceutical markets where orphan-drug reimbursement is possible, while using partners to extend reach where direct commercialization would be less efficient.

3. 1c. How does BioCryst plan to win?

   BioCryst’s main “how to win” is oral differentiation plus specialist execution. ORLADEYO competes in HAE by offering a once-daily oral preventive option in a market long shaped by injectable or infused therapies. More broadly, BioCryst aims to win by selecting targets where small-molecule design can produce clinically useful, commercially practical therapies, then commercializing them with a targeted rare-disease model rather than a mass-market sales force. In effect, the company is betting that convenience, persistence, and focused market access can create a strong position even against larger competitors.

4. 1d. What capabilities must BioCryst have in place?

   To make that strategy work, BioCryst needs strong capabilities in structure-guided drug discovery, rare-disease clinical development, regulatory execution, market access, and patient support. It also needs dependable outsourced manufacturing and quality systems, because it does not rely on a large internal production base. On the commercial side, BioCryst must be good at identifying high-value prescribers and treatment centers, supporting reimbursement, and keeping patients on therapy over time.

5. 1e. What management systems does BioCryst require?

   The required management systems are those of a focused specialty-pharma company: tight pharmacovigilance and regulatory compliance, disciplined portfolio governance, careful cash planning, and detailed tracking of patient starts, persistence, access approvals, and geographic launches. Because BioCryst is still concentrated around one major growth product, coordination between commercial, medical, supply, finance, and R&D functions matters more than a broad divisional structure would suggest.

2. What Are the Current Strategic Initiatives of BioCryst?

• Expand ORLADEYO penetration in HAE prophylaxis. As of FY2024, BioCryst’s most important initiative was continued growth of ORLADEYO, especially by increasing patient starts, supporting persistence, and winning share in a prophylaxis market that includes established injectable competitors. For BioCryst, commercial execution in HAE is not just about new prescriptions; it is about long-term retention in a chronic-therapy setting.

• Broaden international access. BioCryst has continued to pursue reimbursement and commercial expansion outside the United States. In practice, this means adding countries, deepening access in reimbursed markets, and coordinating with partners where BioCryst does not maintain a full direct commercial infrastructure. International expansion is strategically important because HAE is a global orphan market and the addressable patient base is too small to leave reimbursed geographies underdeveloped.

• Generate supporting evidence for ORLADEYO. Beyond the original approval package, BioCryst has emphasized long-term data, medical education, and evidence generation that can support physician confidence, payer discussions, and persistence. In rare disease, especially where patients may be switching from well-known injectables, evidence development remains a commercial tool as much as a scientific one.

• Advance the complement pipeline. BioCryst’s lead pipeline priority beyond ORLADEYO has been its oral factor D program, including BCX10013. This initiative matters because it represents the company’s attempt to replicate its oral-small-molecule strategy in another rare-disease category rather than remain a single-product story.

• Maintain financial discipline while scaling. BioCryst has been explicit about aligning spending with the growth of the ORLADEYO franchise. The strategic aim is to fund commercial expansion and selected R&D without rebuilding the cost structure of a much larger pharmaceutical company before the revenue base warrants it.

• Protect supply continuity. For a company this concentrated in one growth product, manufacturing reliability, inventory planning, and partner coordination are strategic initiatives in their own right. Any avoidable supply disruption would have outsized commercial and reputational consequences.

3. What Is the Business Model of BioCryst?

BioCryst is a product-based rare-disease pharmaceutical company. Customers do not buy a platform or service; they buy approved therapies, primarily ORLADEYO, through specialty distribution and reimbursement channels. The business model is therefore driven by prescription demand, access approvals, refill behavior, pricing, and territory expansion.

What customers actually buy: the core purchase is chronic HAE prophylaxis through ORLADEYO. For a much smaller portion of the business, BioCryst also participates in influenza treatment through RAPIVAB/peramivir-related revenue streams.

Recurring versus one-time revenue: ORLADEYO is the attractive part of the model because it is repeat-driven. Once a patient starts and remains on therapy, revenue can recur through ongoing refills, subject to persistence, coverage, and physician choice. RAPIVAB is more episodic and far less central strategically.

How pricing power works: orphan-drug markets can support premium pricing, but pricing power is not unlimited. Realized price depends on payer negotiations, gross-to-net deductions, reimbursement terms by country, and competitive alternatives such as Takeda’s and CSL’s HAE products. BioCryst’s pricing position is helped by the convenience of an oral option, but it is still bounded by access and evidence.

Why the mix matters: a revenue mix dominated by ORLADEYO is favorable because it is chronic, repeat-driven, and aligned with a focused commercial model. A higher share of revenue from legacy antiviral products would imply a less predictable and lower-strategic-value mix.

What drives margins and cash generation: gross margin benefits from rare-disease pricing and an oral small-molecule format that is generally less operationally complex than biologics. Operating margin and cash generation depend on the pace at which ORLADEYO revenue grows relative to fixed commercial, medical, and R&D costs. The company’s financial logic is straightforward: if ORLADEYO keeps scaling, more of each incremental dollar can support pipeline investment and balance-sheet durability.

4. What Products and/or Services Does BioCryst Sell?

BioCryst is primarily a drug company, not a services company. Its value comes from intellectual property, regulatory approvals, and commercialization capabilities around rare-disease medicines.

• ORLADEYO (berotralstat): BioCryst’s flagship product and primary revenue driver as of FY2024. ORLADEYO is an oral prophylactic therapy for hereditary angioedema attacks and is strategically important because it transformed BioCryst from a development-stage biotech into a commercial rare-disease company.

• RAPIVAB (peramivir): an intravenous antiviral for influenza. This is a real commercial asset, but it is now much less important than ORLADEYO to BioCryst’s growth profile and valuation.

• Pipeline programs: BioCryst’s pipeline, including its oral factor D program led by BCX10013, represents the company’s future growth option beyond ORLADEYO. These are not yet revenue-generating products, but they are strategically significant because they determine whether BioCryst becomes a multi-asset rare-disease company.

The clearest distinction in BioCryst’s portfolio is between legacy/secondary assets such as RAPIVAB and the current growth engine ORLADEYO, with the pipeline serving as the next layer of value creation.

5. What Are the Key Competitors or Peers of BioCryst?

BioCryst does not compete with all of pharma. Its most relevant competitors are concentrated in hereditary angioedema and, for the pipeline, complement-mediated rare diseases.

• Takeda: the most important direct competitor in HAE. Takeda markets Takhzyro for prophylaxis and also has acute HAE products, making it the dominant incumbent benchmark against which ORLADEYO is often judged.

• CSL Behring: another major HAE player, with plasma-derived products such as Haegarda and Berinert. CSL competes primarily through established physician familiarity and biologic/plasma-derived treatment options.

• Pharvaris: a development-stage HAE competitor focused on oral bradykinin B2 receptor antagonists. Strategically, Pharvaris matters because it also advances an oral thesis in HAE.

• KalVista Pharmaceuticals: developing oral HAE therapies, especially for on-demand treatment. Not a direct match to ORLADEYO’s preventive position, but highly relevant as the HAE treatment paradigm evolves.

• Ionis Pharmaceuticals / Otsuka: developing donidalorsen for HAE prophylaxis. This pairing is a meaningful late-stage competitive threat in prevention.

• Astria Therapeutics: developing long-acting HAE prophylaxis candidates. Astria is a pipeline competitor rather than a large commercial incumbent.

• AstraZeneca / Alexion: not a direct HAE competitor, but an important peer in complement-mediated rare diseases. This matters because BioCryst’s factor D program will eventually be judged against established complement players.

• Apellis Pharmaceuticals: another complement-focused rare-disease company with commercial experience in a highly specialized market. More a strategic peer for pipeline comparison than a current direct product rival.

• Novartis: relevant because of its activity in complement biology and rare diseases, including oral complement-pathway approaches. Novartis is a useful comparator for where BioCryst’s pipeline is trying to create value.

For RAPIVAB, BioCryst also faces broader influenza antiviral competition, but that is secondary to the company’s strategic identity, which is now centered on HAE and rare-disease pipeline development.

6. What Is the Marketing Strategy of BioCryst?

BioCryst’s marketing strategy is specialist, evidence-led, and access-aware. This is not a consumer-health model built on mass advertising. In rare disease, the relevant audiences are HAE specialists, allergists, immunologists, treatment centers, specialty pharmacies, payers, and patient communities.

For ORLADEYO, brand messaging is built around the practical value of once-daily oral prophylaxis, but the heavier lift is usually clinical and economic rather than creative. BioCryst needs physicians to be confident in efficacy and tolerability, payers to support access, and patients to stay on therapy. That makes medical affairs, disease education, reimbursement support, and patient services unusually important parts of the go-to-market model.

In this setting, marketing is a supporting capability with real strategic importance. It is not the main moat by itself; the main moat is clinical value plus regulatory position. But smart marketing can improve diagnosis pathways, physician familiarity, patient conversion, and persistence, all of which directly affect a chronic orphan-drug franchise.

7. What Are the Key Customer Segments of BioCryst?

BioCryst’s key customer segments are best understood at two levels: the economic customer and the clinical end user.

• HAE patients and prescribers: the most important end market. These include patients needing long-term prophylaxis and the specialist physicians and HAE centers that influence treatment choice.

• Payers and reimbursement decision-makers: in the United States this includes commercial plans and government-related channels; internationally it includes national health systems and health technology assessment bodies. These entities strongly affect access and realized price.

• Specialty pharmacies and specialty distributors: these are critical commercial intermediaries for ORLADEYO. They are not the ultimate end users, but they are important operational customers.

• Hospitals and institutional purchasers: more relevant to RAPIVAB, where use is episodic and institutional channels matter more than chronic outpatient specialty channels.

• International partners: in markets where BioCryst does not commercialize directly, partners become a key route to patients and a meaningful part of the customer/channel structure.

Overall, BioCryst is specialized rather than diversified. That focus supports efficient commercialization, but it also means the company is meaningfully exposed to one disease area and one primary revenue franchise.

8. What Is the Sales Model of BioCryst?

BioCryst uses a specialty-pharma sales model. In core markets, it sells through a targeted commercial organization that calls on a relatively small universe of specialist physicians and treatment centers. Distribution for ORLADEYO typically runs through specialty pharmacy and specialty distribution channels rather than mass retail pharmacy.

Outside core direct markets, BioCryst supplements its reach with partnerships. That helps the company enter additional countries without building a fully scaled local infrastructure everywhere. The trade-off is that partnered geographies can generate less direct control over execution and economics than wholly owned commercialization.

This channel structure affects growth in several ways:

• Customer intimacy: direct specialist coverage can support better physician engagement and faster feedback on patient barriers.

• Pricing and access: specialty channels help support premium orphan-drug economics, but reimbursement complexity remains high.

• Scalability: a focused field force is more efficient than a broad primary-care model, but expansion still requires careful prioritization of territories and accounts.

• Consultant relevance: because the model is targeted and data-rich, companies like BioCryst can benefit from external help on territory design, patient journey analytics, specialty pharmacy performance, and launch planning.

9. In What Geographies Does BioCryst Operate?

BioCryst’s commercial and operating footprint is international but selective. Its core business is anchored in the United States, with additional activity across Europe and Japan. The company also reaches other markets through commercial partners and distributors.

Operationally, BioCryst is lighter on physical infrastructure than a large pharmaceutical manufacturer. It has corporate and research roots in the United States, including Durham, North Carolina, and a long-standing presence in Birmingham, Alabama. It does not depend on a vast owned manufacturing network; instead, it uses external manufacturing and service partners to support global supply.

Commercially, the company’s most important geography is the United States, but international markets matter for long-term franchise value because rare-disease patient populations are small and dispersed. Europe and Japan are therefore strategically important not just as add-ons, but as necessary pieces of a scaled orphan-drug model.

10. Who Are the Owners of BioCryst?

BioCryst is a publicly traded Nasdaq-listed company. As of recent 2025 proxy and SEC ownership disclosures, it did not have a publicly disclosed controlling shareholder. Ownership has been broadly distributed across institutional investors, healthcare-focused funds, and retail shareholders. Large institutional holders have included firms such as BlackRock and The Vanguard Group, with ownership levels subject to change as 13G and other filings are updated.

11. How Is BioCryst Organized?

As of FY2024, BioCryst reported one reportable segment. That is typical for a focused biopharmaceutical company whose economics are still dominated by one major growth product.

Practically, the company appears organized by function rather than by many autonomous business units. The key operating groups are commercial, medical affairs, research and development, technical operations and quality, regulatory, and general corporate functions such as finance and legal. International commercialization is managed through a mix of direct operations and partner relationships.

This structure has two implications. First, decision-making can be relatively fast because BioCryst is not managing a large portfolio of unrelated divisions. Second, the company is more exposed to cross-functional execution risk: when one product drives most of the economics, coordination across supply, market access, medical, and sales becomes especially important.

12. How Does BioCryst Operate?

On a day-to-day basis, BioCryst operates as a focused specialty-pharma company with an integrated but relatively lean model. Its core operating activities include:

• running commercial operations for ORLADEYO, including physician coverage, specialty distribution support, reimbursement coordination, and patient services;

• managing regulatory, safety, and medical affairs obligations for marketed products;

• overseeing outsourced manufacturing, quality systems, supply planning, and inventory management;

• conducting R&D through internal scientific leadership combined with contract research organizations, clinical sites, and manufacturing partners.

The company’s operational complexity is less about running giant plants and more about coordinating a high-value, low-volume rare-disease ecosystem. Diagnosis rates, payer approvals, patient onboarding, refill persistence, pharmacovigilance, and reliable supply all matter disproportionately. For a company like BioCryst, losing a small number of chronic patients can have a meaningful commercial effect, so execution precision matters more than sheer scale.

13. What Are the Growth Opportunities for BioCryst?

The most plausible growth opportunities for BioCryst are closely tied to public company priorities and the economics of rare disease:

• Deeper HAE penetration: ORLADEYO can grow through additional diagnosed patients, greater physician adoption, and switching from injectable prophylaxis where an oral option is attractive.

• International expansion: new country launches, additional reimbursement wins, and better execution in partner markets can expand the addressable population.

• Lifecycle reinforcement for ORLADEYO: long-term data, persistence support, and targeted evidence generation can help protect and deepen the franchise even without a brand-new indication.

• Pipeline progress in complement-mediated diseases: if BioCryst can show differentiated clinical data with its oral factor D program, it can move from a one-franchise company toward a broader rare-disease platform.

• Selective business development: while not the core of BioCryst’s historical model, a focused licensing or partnership strategy in rare disease could become a sensible growth lever if supported by balance-sheet capacity and commercial fit.

The main constraints are also clear: HAE is a small market; competition is credible and growing; payer pressure can limit realized pricing; BioCryst remains concentrated in one lead franchise; and pipeline value still depends on clinical execution rather than commercial promise alone.

14. What Is the History of BioCryst?

BioCryst was founded in 1986 in Birmingham, Alabama, to apply structure-based drug design to therapeutics. For much of its history, the company looked like a classic small biotech: scientifically differentiated, partner-dependent, and focused on moving programs through development rather than running a scaled commercial engine.

Over time, BioCryst developed antiviral and enzyme-targeting programs, including peramivir, which became RAPIVAB in the United States. RAPIVAB’s approval in 2014 gave the company an approved product, but it did not by itself transform BioCryst’s financial profile.

The defining strategic shift came with ORLADEYO. Its approval in 2020 moved BioCryst into the commercial rare-disease category and reshaped the company’s economics around a chronic, higher-value orphan-drug franchise. Since then, BioCryst’s history has been less about being a research-stage biotech and more about trying to convert a successful first franchise into a sustainable multi-asset company.

15. What Are the Key Suppliers to BioCryst?

Suppliers matter materially to BioCryst because the company relies heavily on third-party manufacturing and external service providers rather than a large internal industrial base. The most important supplier categories are:

• active pharmaceutical ingredient manufacturers for ORLADEYO and pipeline compounds;

• drug-product manufacturers and packagers for finished dosage forms and market-ready inventory;

• specialty logistics, distribution, and pharmacy partners that move product to the channel and support dispensing;

• contract research organizations, labs, and trial service providers that support clinical development.

BioCryst’s public filings emphasize dependence on third parties and, in some cases, limited-source arrangements. Even when specific vendors are not broadly named, the strategic issue is clear: switching qualified suppliers in pharma is slow, regulated, and operationally risky. For a company concentrated in one major commercial product, supplier resilience is a strategic requirement, not just a procurement issue.

16. What Are the Key Brands Owned by BioCryst?

Branding matters at BioCryst, but not in the same way it would at a consumer-products company. In orphan pharma, the decisive levers are clinical profile, label, access, and physician confidence. Even so, BioCryst’s key brands are important commercial assets.

• ORLADEYO: the company’s central brand. Its positioning is straightforward and powerful: a once-daily oral preventive option in hereditary angioedema. The brand’s value comes from convenience, chronic use, and its role as BioCryst’s primary franchise.

• RAPIVAB: a legacy but still relevant brand in influenza treatment. Its market role is narrower and more institutional than ORLADEYO’s.

• BioCryst corporate brand: less important than the product brands, but still relevant in investor communications, patient advocacy relationships, recruiting, and scientific credibility.

So branding is important but not the main strategic lever. For BioCryst, brand strength follows from evidence, access, and patient experience more than from broad promotional spend.

17. How Does the Supply Chain of BioCryst Function?

BioCryst’s supply chain is built around outsourced pharmaceutical manufacturing and specialty distribution. The basic flow is: source active ingredient and other inputs, manufacture and package finished product through qualified third parties, release batches through regulated quality processes, and distribute to specialty channels or partners in the relevant markets.

For ORLADEYO, the oral dosage form is strategically helpful. Compared with many biologic rare-disease therapies, an oral capsule generally reduces some cold-chain and administration complexity. That does not remove risk, but it can make logistics, storage, and patient access more straightforward than for infused or injectable alternatives.

The main supply-chain issues for BioCryst are reliability, regulatory compliance, and inventory planning. Because patient populations are small, stock-outs can be highly damaging even if the absolute unit volumes are not large. At the same time, carrying too much inventory can create working-capital pressure and expiry risk. This balance is especially important when a single product accounts for most of the company’s commercial value.

18. What Are the Key Assets of BioCryst?

BioCryst is not asset-heavy in the industrial sense; it does not depend on a vast owned manufacturing footprint. Its most important assets are instead intellectual, regulatory, and commercial.

• ORLADEYO intellectual property and regulatory rights: these are the company’s most important value-bearing assets.

• Rare-disease commercial infrastructure: physician relationships, market-access know-how, specialty distribution processes, and patient-support capabilities are meaningful assets for a focused company.

• Pipeline know-how and data: BioCryst’s internal discovery capabilities and clinical data packages underpin future optionality.

• Cash and financing capacity: for a biotech-to-commercial transition company, liquidity is itself a strategic asset because it determines how much development risk the business can absorb.

This asset mix affects returns in an important way: success depends less on asset utilization of plants and more on exclusivity, clinical differentiation, and capital discipline.

19. What Is the Technology Strategy of BioCryst?

BioCryst’s technology strategy is centered on structure-guided drug discovery and the development of oral small molecules against carefully chosen biological targets. This is not a customer-facing software strategy; it is a scientific and development strategy.

The company’s historical identity has been built around understanding enzyme and pathway biology, designing molecules with suitable potency and pharmacokinetics, and then applying that capability to diseases where oral therapy can be genuinely differentiated. ORLADEYO is the clearest proof point of this approach in commercial form.

As a result, technology at BioCryst serves two roles. First, it is an internal discovery engine that guides target selection and molecule optimization. Second, it is a strategic filter: BioCryst appears to prefer programs where oral chemistry can create a practical competitive edge rather than simply replicate what larger biologics companies already do well.

20. What Is the R&D Strategy of BioCryst?

BioCryst’s R&D strategy is to concentrate on a limited number of rare-disease programs where it believes oral small molecules can be clinically and commercially differentiated. This is a narrower strategy than that of a diversified pharma company, and that is intentional. BioCryst does not need many shots on goal; it needs a few programs with meaningful probability-adjusted value.

As of FY2024, the company’s lead growth story beyond ORLADEYO was its oral factor D program, including BCX10013, in complement-mediated diseases. This fits the broader BioCryst pattern: select a biologically validated pathway, try to create a differentiated oral profile, and target a specialized market where a small commercial organization could plausibly succeed.

BioCryst’s R&D strategy also includes ongoing evidence generation for ORLADEYO, which is common in rare disease because post-approval data can support physician confidence, reimbursement, and lifecycle durability. Operationally, the company combines internal scientific leadership with significant use of external research, clinical, and manufacturing partners.

21. What Is the Finance Strategy of BioCryst?

BioCryst’s finance strategy has been shaped by a central objective: use ORLADEYO’s growth to improve self-funding capacity while preserving enough liquidity to support pipeline development. For a company of BioCryst’s size, capital allocation is inseparable from strategy.

In practical terms, that means several things:

• prioritizing investment behind the ORLADEYO franchise because it is the source of recurring revenue;

• keeping the commercial and corporate cost base disciplined relative to revenue growth;

• concentrating R&D spend on programs with the highest strategic and economic potential;

• managing leverage, royalty, or other financing arrangements so that near-term capital needs do not overwhelm long-term value creation.

Historically, BioCryst, like many biotech companies, has relied on external financing at different stages. The strategic change is that recurring ORLADEYO revenue creates a path toward greater financial independence. Whether that path fully materializes depends on continued commercial execution and pipeline discipline.

22. How Companies Like BioCryst Leverage Independent Consultants through Umbrex

For a company like BioCryst, independent consultants are most useful on high-stakes projects that are too important for a generalist freelancer but too narrow to require a full traditional consulting team. Umbrex has built a global community of more than 8,000 independent management consultants across more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. Companies like BioCryst use Umbrex when they want top-tier strategic and operational talent in areas such as strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI, but do not need the full overhead of a large consulting engagement.

Representative projects Umbrex consultants could support for a company like BioCryst include:

• Global HAE growth strategy: assess where ORLADEYO has the best incremental share opportunities by patient segment, physician type, and geography.

• Patient journey and persistence improvement: diagnose where patients drop out between prescription, reimbursement approval, dispensing, and long-term adherence.

• International market access prioritization: build a country-by-country reimbursement and launch sequencing plan for additional ORLADEYO expansion.

• Rare-disease field force design: optimize territory structure, account targeting, call plans, and specialist coverage in the United States or Europe.

• Specialty pharmacy and patient-services redesign: improve onboarding speed, case-management effectiveness, and refill conversion.

• Supply-chain resilience assessment: evaluate manufacturing concentration risk, inventory policy, and dual-sourcing options for ORLADEYO and pipeline assets.

• Pipeline commercial readiness: develop early launch assumptions, market sizing, and target product profile-based commercial scenarios for complement programs such as BCX10013.

• R&D portfolio prioritization: create a stage-gate framework to compare rare-disease pipeline investments, partnering options, and stop/go decisions.

• Path-to-self-funding operating model: pressure-test SG&A scaling, cash needs, and organizational design under different ORLADEYO growth cases.

• Business development support: screen adjacent rare-disease licensing opportunities that fit BioCryst’s oral-small-molecule strategy and specialist commercial model.